{
"id":"mk19_a_gm_t53",
"number":53,
"bookId":"gm",
"title":{
"__html":"Pharmacotherapy for Alcohol Use Disorder"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"ea0f75",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 53. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gm_t53"
}
]
},
"Pharmacotherapy for Alcohol Use Disorder"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"01d822",
"class":"col hd l",
"children":[
"Medication and Typical Dosage",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1b1583",
"class":"col hd l",
"children":[
"Indication"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7a3d46",
"class":"col hd l",
"children":[
"Mechanism"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"017e8f",
"class":"col hd l",
"children":[
"Side Effects"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f4c6f8",
"class":"col hd l",
"children":[
"Notes"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ce64a3",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Naltrexone"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"f2d464",
"class":"cell txt l",
"children":[
"Oral, 50-100 mg daily"
]
},
" ",
{
"type":"p",
"hlId":"814d6a",
"class":"cell txt l",
"children":[
"Injectable, 380 mg monthly"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c16435",
"class":"cell txt l",
"children":[
"Relapse prevention"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"246b42",
"class":"cell txt l",
"children":[
"Opioid antagonist that may reduce the subjective reward associated with alcohol use"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1e38df",
"class":"cell txt l",
"children":[
"Nausea, indigestion, headache, fatigue"
]
},
" ",
{
"type":"p",
"hlId":"45feea",
"class":"cell txt l",
"children":[
"Depressive symptoms"
]
},
" ",
{
"type":"p",
"hlId":"20994b",
"class":"cell txt l",
"children":[
"Rarely, medication-associated hepatitis"
]
},
" ",
{
"type":"p",
"hlId":"cbb4a5",
"class":"cell txt l",
"children":[
"Potential for precipitated opioid withdrawal with opioid use"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d83ecc",
"class":"cell txt l",
"children":[
"Contraindicated with concurrent opioid use; offer with concomitant opioid use disorder",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" ",
{
"type":"p",
"hlId":"be7628",
"class":"cell txt l",
"children":[
"Avoid in patients with decompensated cirrhosis, acute hepatitis, or liver failure",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"; use with caution in patients with hepatitis or compensated cirrhosis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cb0d2c",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Acamprosate"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"befefb",
"class":"cell txt l",
"children":[
"666 mg three times daily"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c16435",
"class":"cell txt l",
"children":[
"Relapse prevention"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"702892",
"class":"cell txt l",
"children":[
"May antagonize glutamate-mediated neuronal hyperexcitability and reduce prolonged (but not acute) withdrawal symptoms"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f9d3db",
"class":"cell txt l",
"children":[
"Diarrhea, nausea/vomiting, myalgia, rash, dizziness, palpitations"
]
},
" ",
{
"type":"p",
"hlId":"ec4f99",
"class":"cell txt l",
"children":[
"Rarely associated with kidney impairment"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"10d2a2",
"class":"cell txt l",
"children":[
"Can be used in patients with alcohol-related liver disease"
]
},
" ",
{
"type":"p",
"hlId":"d5173d",
"class":"cell txt l",
"children":[
"Avoid in patients with severe kidney impairment (eGFR <30 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
"); second-line therapy in mild to moderate kidney impairment and requires reduced dosage",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" ",
{
"type":"p",
"hlId":"aea6ea",
"class":"cell txt l",
"children":[
"May be used with naltrexone"
]
},
" ",
{
"type":"p",
"hlId":"37d22c",
"class":"cell txt l",
"children":[
"Medication adherence may be challenging"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"905fb0",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Disulfiram"
]
},
" "
]
},
" ",
{
"type":"p",
"hlId":"34eb87",
"class":"cell txt l",
"children":[
"250-500 mg daily"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3a9537",
"class":"cell txt l",
"children":[
"Prevention of drinking and relapse prevention"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ed192b",
"class":"cell txt l",
"children":[
"Aldehyde dehydrogenase inhibition results in acetaldehyde accumulation with alcohol use, leading to unpleasant symptoms (alcohol-disulfiram reaction)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8f06cb",
"class":"cell txt l",
"children":[
"Drowsiness, rash"
]
},
" ",
{
"type":"p",
"hlId":"cbaa57",
"class":"cell txt l",
"children":[
"Rarely, medication-associated severe hepatotoxicity, optic neuritis, peripheral neuropathy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2f4bb5",
"class":"cell txt l",
"children":[
"Potential for many drug-drug interactions"
]
},
" ",
{
"type":"p",
"hlId":"19dc2c",
"class":"cell txt l",
"children":[
"Patient must be abstinent ≥12 h before medication administration"
]
},
" ",
{
"type":"p",
"hlId":"877ff7",
"class":"cell txt l",
"children":[
"Avoid in patients with hepatic impairment or cardiovascular disease"
]
},
" ",
{
"type":"p",
"hlId":"a09fb1",
"class":"cell txt l",
"children":[
"Most appropriate for patients with strong motivation to be abstinent and with support to promote medication adherence"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"eGFR = estimated glomerular filtration rate."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Naltrexone, disulfiram, and acamprosate are all FDA pregnancy category C (animal studies indicate potential fetal risk or have not been conducted, and no or insufficient human studies have been done; drugs in this category should be used in pregnant or lactating women only when potential benefits justify potential risk to the fetus or infant)."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Information from Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry. 2018;175:86-90. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29301420",
"target":"_blank"
},
"children":[
"PMID: 29301420"
]
},
" doi:10.1176/appi.ajp.2017.1750101"
],
[
"Adapted with permission from Edelman EJ, Fiellin DA. In the clinic. Alcohol use. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/AITC201601050",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2016;164:ITC10. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26747315",
"target":"_blank"
},
"children":[
"PMID: 26747315"
]
},
".. © 2016, American College of Physicians."
]
]
}